Passage Bio
Manufacturing · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2005 Market St Fl 39, Philadelphia, Penn...Phone Number
(267) 866-0311Website
www.passagebio.comRevenue
$12.7 MillionStock Symbol
PASGIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Passage Bio
Founded in 2017, Passage Bio is a genetic medicines company based in Philadelphia, PA that is developing a portfolio of six life transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases.Explore more
Passage Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Passage Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Passage Bio
Check if Passage Bio has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Passage Bio launches new products
Funding: Get notified immidiatlly once Passage Bio has new funding data
Passage Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Passage Bio had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check out if Passage Bio is spiking on competitors!
Earning: See what the market has to say on Passage Bio recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Passage Bio
Compare insights from companies similar to Passage Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Passage Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Passage Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Passage Bio.
Passage Bio financials insights
Gather financial insights about Passage Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$115.5M
Series B
$110M
2020
Stock Offering
$216M
Passage Bio Tech Stack
A closer look at the technologies used by Passage Bio
See more technologies
Most Recent Scoops
Project
Passage Bio has announced that REM-422 is currently being evaluated in a Phase I/II clinical trial in patients with ACC including a completed Phase I dose escalation phase in 69 patients and an ongoing Phase II confirmatory cohort targeting 40 to 50 biomarker-positive patients as well as a Phase I study in AML and high-risk MDS. The ARIA study is currently enrolling in the Phase II portion, which is an open-label, non-randomized, multi-center trial.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Passage Bio has announced encouraging clinical data from the ongoing ARIA study of REM-422 in patients with ACC, presented at the 2026 ASCO Annual Meeting, demonstrating dose-proportional increases in exposure across all dose levels tested and reductions in MYB mRNA and protein levels in tumor biopsies.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Passage Bio has announced that REM-422 targets adenoid cystic carcinoma (ACC), a solid tumor with over 1,500 new cases annually in the US and a prevalent population of 13,000 to 16,000 people, for which there are currently no approved treatment options. Approximately 60% to 65% of ACC patients are MYB poison exon biomarker positive and are potential candidates for REM-422 treatment.
Medical Research, Pharmaceuticals
Project
Passage Bio has announced that initial data from the ongoing Phase II cohort of REM-422 in ACC are expected in mid-2027, and that enrollment has begun in the Phase I study of REM-422 in AML and high-risk MDS, with strong preliminary anti-tumor activity observed during dose escalation and top-line data expected in mid-2027. Dose escalation is ongoing to determine the recommended Phase II dose for REM-422 in AML and high-risk MDS.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Medical Research, Pharmaceuticals
Passage Bio News & Media
Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript
Passage Bio, Inc. (PASG) M&A Call June 24, 2026 4:30 PM EDTCompany ParticipantsKathleen Borthwick - Senior VP, CFO, Principal Financial Officer &...Spurned by FDA, Passage Bio finds exit through merger with Remix - Fierce Biotech
Passage Bio, the Philadelphia-based gene therapy outfit that launched a strategic review earlier this year after tough feedback from the FDA, has found an exit in anPassage Bio and Remix Therapeutics Announce Merger Agreement
Combined company to operate as Remix Therapeutics and advance Remix’s pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their originPassage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside?
Passage Bio Inc (NASDAQ:PASG) is one of the best gene therapy stocks to buy in 2026. While the stock is down around 50% year-to-date, analysts see it surging 125% over the next 12 months. On April 20, Passage Bio said it was reviewing its strategic alternatives to maximize shareholder value. It has tapped Wedbush PacGrow […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Passage Bio
Sign Up For FreeTo access detailed company insights
Founded in 2017, Passage Bio is a genetic medicines company based in Philadelphia, PA that is developing a portfolio of six life transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases.... Read More
